Grufity logo
Grufity logo

Latest Octagon Capital Advisors LP Stock Portfolio

$1.11Billion | No. of Holdings #26

Octagon Capital Advisors LP Performance

2026 Q2+25.99%
YTD+38.17%
2025+104.18%

About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings

On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $1.1 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Octagon Capital Advisors LP are , , . The fund has invested 16.1% of it's portfolio in DIANTHUS THERAPEUTICS INC and 12.5% of portfolio in DEFINIUM THERAPEUTICS INC. <br><br> The fund managers got completely rid off CENTESSA PHARMACEUTICALS PLC (CNTA), KALVISTA PHARMACEUTICALS INC (KALV) and TERNS PHARMACEUTICALS INC (TERN) stocks. They significantly reduced their stock positions in TREVI THERAPEUTICS INC (TRVI), CONTEXT THERAPEUTICS INC (CNTX) and PRECISION BIOSCIENCES INC (DTIL). Octagon Capital Advisors LP opened new stock positions in SUMMIT THERAPEUTICS INC (SMMT), ADLAI NORTYE LTD and FAETH THERAPEUTICS INC (SNSE). The fund showed a lot of confidence in some stocks as they added substantially to PHARVARIS N V (PHVS), ABIVAX SA and TAYSHA GENE THERAPIES INC (TSHA).
Octagon Capital Advisors LP Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$1.11Billion
  as of Aug 14, 2026

Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500

Our best estimate is that Octagon Capital Advisors LP made a return of 25.99% in the last quarter. In trailing 12 months, it's portfolio return was 202.96%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
summit therapeutics inc18,212,500
adlai nortye ltd10,749,200
faeth therapeutics inc9,025,250
gyre therapeutics inc6,289,600
New stocks bought by Octagon Capital Advisors LP

Additions

Ticker% Inc.
pharvaris n v176
abivax sa46.68
definium therapeutics inc20.9
taysha gene therapies inc9.41
Additions to existing portfolio by Octagon Capital Advisors LP

Reductions

Ticker% Reduced
trevi therapeutics inc-78.79
context therapeutics inc-41.9
precision biosciences inc-39.64
ocular therapeutix inc-34.47
kymera therapeutics inc-27.06
dianthus therapeutics inc-5.39
Octagon Capital Advisors LP reduced stake in above stock

Sold off

Ticker$ Sold
kalvista pharmaceuticals inc-29,188,500
lexeo therapeutics inc-6,314,000
perspective therapeutics inc-3,300,780
centessa pharmaceuticals plc-29,790,000
bridgebio oncology therapeut-6,435,050
terns pharmaceuticals inc-27,941,600
evommune inc-3,298,420
Octagon Capital Advisors LP got rid off the above stocks

Sector Distribution

Octagon Capital Advisors LP has about 66.6% of it's holdings in Others sector.

  • Others
  • Healthcare
Sector%
Others66.6
Healthcare33.4

Market Cap. Distribution

Octagon Capital Advisors LP has about 1.7% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • MID-CAP
  • SMALL-CAP
  • LARGE-CAP
  • MICRO-CAP
Category%
UNALLOCATED66.6
MID-CAP19.4
SMALL-CAP9.9
LARGE-CAP1.7
MICRO-CAP1.6

Stocks belong to which Index?

About 19.3% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
Index%
Others80.7
RUSSELL 200019.3
Top 5 Winners (%)%
definium therapeutics inc
120.5 %
aktis oncology inc
80.2 %
arrivent biopharma inc
50.6 %
TSHA
taysha gene therapies inc
49.0 %
bioage labs inc
40.1 %
Top 5 Winners ($)$
definium therapeutics inc
75.8 M
dianthus therapeutics inc
25.7 M
arrivent biopharma inc
23.0 M
TSHA
taysha gene therapies inc
21.7 M
abivax sa
18.3 M
Top 5 Losers (%)%
CNTX
context therapeutics inc
-62.3 %
GOSS
gossamer bio inc
-49.9 %
UNCY
unicycive therapeutics inc
-28.7 %
DBVT
dbv technologies s a
-21.5 %
Top 5 Losers ($)$
CNTX
context therapeutics inc
-8.6 M
DBVT
dbv technologies s a
-2.6 M
UNCY
unicycive therapeutics inc
-1.9 M
GOSS
gossamer bio inc
-1.3 M

Octagon Capital Advisors LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Octagon Capital Advisors LP

Octagon Capital Advisors LP has 26 stocks in it's portfolio. About 78.5% of the portfolio is in top 10 stocks. CNTX proved to be the most loss making stock for the portfolio. was the most profitable stock for Octagon Capital Advisors LP last quarter.

$1.09BTotal Value
33.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Octagon Capital Advisors LP, last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
DBVT
Dbv Technologies S A

Dbv Technologies S A

DBVT
Octagon Capital Advisors LP's holding in Dbv Technologies S A over time
0.85%574,200
$9.42M
0.85%
unchanged 0 percentunchanged
PHVS
Pharvaris N V

Pharvaris N V

PHVS
Octagon Capital Advisors LP's holding in Pharvaris N V over time
1.42%456,721
$15.79M
1.42%
increased 176.8 percentadded
SMMT
Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT
Octagon Capital Advisors LP's holding in Summit Therapeutics Inc over time
1.64%1,250,000
$18.21M
1.64%
new position
Com
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc

Octagon Capital Advisors LP's holding in Dianthus Therapeutics Inc over time
16.14%1,841,670
$179.53M
16.14%
decreased 5.39 percentreduced